Drug intelligence / Profile preview

PTI 101

Development stage: Preclinical
Lead developer: Pericor Science
Modality: Small Molecules

Overview

PTI-101 is a small molecule direct thrombin inhibitor (Factor IIa inhibitor) originally developed by Pericor Science. It was designed to target the coagulation cascade for the treatment of various cardiovascular diseases. By inhibiting thrombin, the drug prevents the conversion of fibrinogen to fibrin, thereby reducing blood clot formation and preventing thrombosis. Its development status is currently listed as pending, indicating that active clinical progression may be stalled or the program is in an early, non-disclosed stage.

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on PTI 101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTI 101.

Explore the full profile